Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 5/20 | 0.68 |
| ▸ | CTSB | P07858 | 5/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.68 |
| ▸ | KDR | P35968 | 2/20 | 0.64 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.60 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.59 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.59 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.58 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.55 |
| ▸ | MAOB | P27338 | 2/20 | 0.54 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.52 |
| ▸ | APP | P05067 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29535965 | 1.00 | CTSL (0.68) | CTSLCTSBTDP1KDRABCB1 | |
| Echinatin SCHEMBL29466900 | 0.82 | CTSL (1.00) | CTSLCTSBTDP1CYP1A1CYP1B1 | |
| Echinatin SCHEMBL618086 | 0.82 | CTSL (1.00) | CTSLCTSBTDP1CYP1A1CYP1B1 | |
| Echinatin SCHEMBL7193984 | 0.82 | CTSL (1.00) | CTSLCTSBTDP1CYP1A1CYP1B1 | |
| SCHEMBL19782822 | 0.81 | KDR (0.78) | KDRABCB1MAOB | |
| SCHEMBL26113846 | 0.79 | CTSB (0.86) | CTSLCTSBTDP1CYP1A1CYP1B1 | |
| SCHEMBL20340332 | 0.77 | CTSL (0.84) | CTSLCTSBTDP1CYP1A1CYP1B1 | |
| SCHEMBL20340331 | 0.77 | CTSL (0.84) | CTSLCTSBTDP1CYP1A1CYP1B1 | |
| SCHEMBL28817357 | 0.76 | MAOB (0.62) | CTSLCTSBKDRABCB1PTPN1 | |
| SCHEMBL28817356 | 0.76 | MAOB (0.62) | CTSLCTSBKDRABCB1PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250376441-A1 | NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | UNIV YONSEI IACF (KR) | 2025-12-11 | — | — | US | disclosed |
| US-12447137-B2 | Composition for prevention, amelioration, or treatment of cancer | EWHA University—Industry Collaboration Foundation (KR) | 2025-10-21 | — | — | US | disclosed |
| US-20220226263-A1 | Composition for Prevention, Amelioration, or Treatment of Cancer | CHA UNIVERSITY INDUSTRY-ACADEMIC COOOPERATION FOUNDATION (KR) | 2022-07-21 | — | — | US | disclosed |
| EP-3977988-A1 | COMPOSITION FOR PREVENTION, AMELIORATION, OR TREATMENT OF CANCER | Ewha University-Industry Collaboration Foundation (KR) | 2022-04-06 | — | — | EP | disclosed |
| WO-2020242201-A1 | COMPOSITION FOR PREVENTION, AMELIORATION, OR TREATMENT OF CANCER | 이화여자대학교 산학협력단 | 2020-12-03 | — | — | WO | disclosed |
| WO-2020184998-A1 | COMPOSITION FOR PREVENTING, ALLEVIATING OR TREATING METABOLIC DISEASES | 연세대학교 산학협력단 | 2020-09-17 | — | — | WO | disclosed |
| US-20200190024-A1 | NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | CHA UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2020-06-18 | — | — | US | disclosed |
| US-20200190024-A1 | NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | CHA UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2020-06-18 | — | — | US | disclosed |
| EP-3626703-A1 | NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | Industry-Academic Cooperation Foundation, Yonsei University (KR) | 2020-03-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190024-A1 | NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | PRKAA1, PRKAA2, PRKAG1 | CTSL 3640/4885CTSB 2585/4885TDP1 1072/4885 |
| US-20220226263-A1 | Composition for Prevention, Amelioration, or Treatment of Cancer | FABP2, FABP1, TSG101 | CTSL 1822/4885CTSB 897/4885TDP1 3141/4885 |
| US-20250376441-A1 | NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | PRKAA1, PRKAA2, PRKAG1 | CTSL 3640/4885CTSB 2585/4885TDP1 1072/4885 |
| US-12447137-B2 | Composition for prevention, amelioration, or treatment of cancer | GSTO1, FABP1, GSTK1 | CTSL 2353/4885CTSB 1055/4885TDP1 4666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.